CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

CSL Behring has signed a deal with US firm BrightInsight to develop digital health products to help patients with rare diseases manage their conditions. The partnership will allow CSL Behring to make ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines committee ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

Good morning, everyone. Thank you for joining CSL's results presentation for the first half of the 2026 financial year. I'm Mark Dehring, CSL's Head of Investor Relations. Please note, this briefing ...

That’s the scale of the upheaval inside Australia’s global pharma, with the bloody sacking of its chief executive just as the US-born boss was about to release the company’s first half accounts. The ...

Shares in Commonwealth Bank bounced after it revealed a $5.4 billion half-year profit leading the ASX higher. CSL’s share price has now halved in 18 months, shredding more than $70 billion of ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

CSL Ltd (ASX: CSL) shares are marching higher today. Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock closed yesterday trading for $181.70. As we head into the Thursday lunch hour, shares are ...

Let's start with CSL's leadership change, because it sets the tone. Paul McKenzie has stepped down as chief executive, and the board has appointed long-time CSL executive and current director Gordon ...

The ASX 200 closed slightly lower, and the CSL chief executive stepped down abruptly ahead of tomorrow's half-year results. Catch up on the day's events and insights from our business reporters on the ...